SCHEMBL4404035

SCHEMBL4404035

N#Cc1ccc[c]c1-c1ccccc1OC(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.36
PGR P06401 1/20 0.36
SLC22A12 Q96S37 3/20 0.36
SCN9A Q15858 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD11B1 P28845 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
PDE2A O00408 1/20 0.34
DHODH Q02127 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE10A Q9Y233 1/20 0.34
PDK2 Q15119 1/20 0.34
PTPN5 P54829 1/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RORC P51449 1/20 0.33
TRPA1 O75762 1/20 0.33
BCAT2 O15382 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2224755 0.81 AR (0.45) ARPGRALDH1A1KDM4EMAPT
SCHEMBL27961681 0.80 AR (0.42) ARPGRSLC22A12SCN9AL3MBTL1
SCHEMBL1206349 0.78 ESR2 (0.44) ARALDH1A1KDM4EPDK2PTPN5
SCHEMBL16719326 0.78 ALDH1A1 (0.40) SCN9AL3MBTL1ALDH1A1HSD11B1KDM4E
SCHEMBL103547 0.76 GAA (0.46) ARPGRSLC22A12ALDH1A1POLB
SCHEMBL134889 0.75 KDM5A (0.36) ARPGRSCN9AALDH1A1KDM4E
SCHEMBL15155502 0.75 CYP11B1 (0.39) L3MBTL1ALDH1A1KDM4EPDK2PTPN5
SCHEMBL2961646 0.73 TSHR (0.31) SLC22A12ALDH1A1KDM4EMAPTPDK2
SCHEMBL2961647 0.73 SLC22A12 (0.35) SLC22A12SCN9AHSD11B1
SCHEMBL2686921 0.73 KCNN4 (0.39) SCN9AL3MBTL1ALDH1A1HSD11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2101585-A1 DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Cenerx Biopharma, Inc. (US) 2009-09-23 EP disclosed
WO-2008066874-A1 DIALKYLAMINO ALKYL ESTERS OF PIVAGABINE AS MEDICAMENTS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS CENERX BIOPHARMA, INC. (US) 2008-06-05 WO disclosed
EP-1865962-A2 USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS Arcadia Pharmaceuticals Inc. (US) 2007-12-19 EP disclosed
WO-2007038169-A2 MULTI-VALENT GUANIDINIUM COMPOUNDS FOR MOLECULAR TRANSLOCATION ACROSS CELLULAR MEMBRANES AND EPITHELIAL TISSUES NITTO DENKO CORPORATION (JP) 2007-04-05 WO disclosed
WO-2006107948-A9 USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS ACADIA PHARM INC (US) 2007-02-22 WO disclosed
WO-2006107948-A2 USE OF N-DESMETHYLCLOZAPINE AND RELATED COMPOUNDS AS DOPAMINE STABILIZING AGENTS ACADIA PHARMACEUTICALS INC. (US) 2006-10-12 WO disclosed